Medicare Advantage coverage denials rise for doctor-recommended care
HHS watchdog finds major Medicare Advantage insurers deny post-acute care at extraordinarily high rates—with 95% of appeals overturned—sparking debate over insurer profit motives versus prior authorization necessity.
Objective Facts
Two HHS Office of Inspector General reports released June 8, 2026, reviewed prior authorization data from June 2024 for the 19 largest Medicare Advantage plans, covering 29.3 million enrollees. The reports found that 65% of long-term acute care hospital requests were denied, 54% of inpatient rehab facility requests were denied, and 95% of appealed skilled nursing facility denial decisions were overturned. UnitedHealthcare, CVS Health and Humana had the highest denial rates for those services, in some cases rejecting prior authorization requests more than 70% of the time. When skilled nursing facility denials were appealed, Medicare Advantage organizations overturned 95 percent in favor of the enrollee, with the extremely high overturn rate indicating that some enrollees were initially denied medically necessary care. Hospitals and health systems continue to sever ties with certain Medicare Advantage plans in 2026, citing persistent frustrations with prior authorization denials and slow reimbursement from insurers.
Left-Leaning Perspective
A group of Democratic senators led by Elizabeth Warren urged the Centers for Medicare and Medicaid Services to rein in abuses from Medicare Advantage insurers, alleging that the program is rife with waste, fraud and abuse. Senator Richard Blumenthal joined Senate Democrats in writing to HHS Secretary Robert F. Kennedy Jr., urging them to crack down on abuses by private insurers in Medicare Advantage that overcharge taxpayers, raise costs for patients, and create barriers to access care. Blumenthal's Senate Permanent Subcommittee on Investigations report detailed how the nation's three largest Medicare Advantage insurers use prior authorization to target stays in skilled nursing facilities, inpatient rehabilitation facilities, and long-term acute care hospitals in order to boost their profits. The left frames these denials as systematic profit-driven abuse requiring regulatory crackdown and contract termination.
Right-Leaning Perspective
Mainstream right-leaning outlets and commentators have cautiously engaged with the denials issue while emphasizing cost containment and program sustainability. Conservative healthcare policy expert Michael Baker of the American Action Forum warned that adding AI-based prior authorization through third parties might increase administrative burden and delay beneficiary care, questioning the administration's approach to reform. Baker cautioned against using untested artificial intelligence and algorithmic decision logic in prior authorization processes. Representative David Schweikert, an oversight subcommittee chair, stated he is a fan of managed care using incentives for organizations to help people get healthier, but noted that in Medicare Advantage, incentives are misaligned and the program is more expensive than traditional Medicare. The right acknowledges denial problems but frames them in the context of cost control and market efficiency, not deliberate profit-seeking.
Deep Dive
Medicare Advantage has grown to cover more than half of eligible seniors, creating a structural dynamic where private insurers receive fixed capitated payments regardless of utilization. The HHS OIG reports in June 2026 documented extraordinary variation in denial rates—CVS denying 80% of long-term care requests while some peers denied 4-8%—and consistently high appeal overturn rates (95% for SNF denials) that suggest initial determinations are often medically inappropriate. The core factual dispute is narrow: everyone agrees denials are rising and appeals are frequently overturned. The political disagreement centers on causation and remedy. The left attributes high denials to systematic profit-seeking enabled by MA's capitated payment model, which removes revenue incentives to provide care. Democrats point to internal company documents (uncovered by Senate investigations) showing deliberate automation of denials and to the fact that for-profit plans deny more than nonprofit plans. Their solution ranges from comprehensive reform (tighter standards, physician review mandates) to abolition. The right and insurers counter that denials reflect appropriate cost-containment for medically unnecessary care; they note that documentation errors and clinical disagreement about medical necessity account for many initial denials. Some conservatives question whether new AI-driven solutions improve efficiency or simply shift the burden. The Trump administration has taken a mixed stance—increasing MA payment rates (favoring insurers) while omitting some Biden-era regulatory guardrails on AI use, yet also proposing electronic prior authorization standards and reporting requirements. What both sides underweight: the structural incentives are genuinely misaligned. CMS pays MA plans a fixed amount per enrollee but traditional Medicare pays for services rendered. This creates an intrinsic pressure in MA plans to constrain utilization. Whether denials are "profit-driven abuse" (left framing) or "appropriate management of low-value care" (right framing) partly depends on clinical evidence about which services are truly low-value—and that evidence often does not exist at the granular level MA plans operate. The extremely high appeal overturn rates do suggest that initial denials are frequently wrong by the plans' own standards, raising questions about training, system design, or whether the threshold for initial denials is intentionally aggressive.